Competition uprising!PB 1402 may soon be extinct...
Fellow competitors are finding their own versions.
APC: 1/4 the dilution and a higher stock price to boot!
Q is: Which one will go first? One of them will and one may be too late!!!!
Advanced Proteome Therapeutics Files Patent Application on Swift Linkage Multivalent Technology
Press Release
VANCOUVER, BRITISH COLUMBIA – (Marketwire – 10/20/09) - In continuing efforts to advance the field of Protein Modification Technologies, Advanced Proteome Therapeutics ("APT") has filed what it believes is a landmark patent application this month on inventions related to its Swift Linkage Multivalent Technology (SMLT). This Patent, along with previous discoveries, represents a milestone in the company’s development and is a significant step toward commercialization.
Protein therapeutics is the fastest growing segment of the pharmaceutical market, with sales projected to be in the 75 billion dollar range by 2013. The Company feels it is well positioned, by virtue of discoveries related to SLMT, to capitalize on this growing market with its own internal projects as well as those of potential partners.
This advanced technology is currently being applied internally to protein targets aimed at treating cancer, Crohn’s disease, arthritis, obesity, atherothrombosis and plaque rupture. In conjunction with the Company’s internal progress, this patent filing allows the Company to foster relationships with potential partners, and/or customers that desire to utilize APT technology to further the development of their own programs.
The Company believes that the technology expands commercial opportunities for APT in certain subfields of protein therapeutics that have been especially challenging, providing APT with a competitive edge, and further validating its corporate strategy.
About Swift Linkage Multivalent Technology - Invented by APT to expand the repertoire of entities that can be rapidly linked to protein sites to generate products for development, the technology enables the rapid attachment of a desired entity to a modified site on a protein surface site-specifically, and to the fullest extent. SMLT has been demonstrated in several instances in APT programs to be capable of providing homogeneous products and may offer distinct technological advantages in the synthesis and manufacturing process of new protein therapeutics.